12th International Congress on Myeloproliferative Neoplasms
Playback speed
10 seconds
Moving Beyond JAKi: Ruxolitinib Failure, Newly Approved and in Development JAKi, & Novel Therapies (JAKi Combo & Novel Agents)
114 views
November 12, 2019
Comments 0
Login to view comments.
Click here to Login
Latest Advances in Myeloproliferative Neoplasms